Judge gives initial approval to Actavis $20m antitrust deal

A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Tris blocks Actavis’ ADHD generic

10 December 2020 New Jersey-based Tris Pharma has won a ruling blocking Teva-owned Actavis from launching a generic version of attention deficit and hyperactivity disorder drug Quillivant XR.

Generics

Teva charged in DoJ antitrust probe into generic drug price-fixing

26 August 2020 Teva Pharmaceuticals has been charged with conspiring to fix prices, rig bids, and allocate customers for generic drugs, the US Department of Justice has announced.

Americas

Amneal and others pay $1.5m to settle antitrust suit over Alzheimer’s drug

20 August 2019 Amneal and three other generic makers have agreed to pay $1.54 million to settle a class-action lawsuit, which alleged the companies engaged in an unlawful scheme to maintain their monopoly over an Alzheimer’s drug.

More features

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Judge gives initial approval to Actavis $20m antitrust deal

More on this story

Editor's picks

Editor's picks

More features